Long-term survival following molecular-targeted therapy for intramedullary non-small-cell lung cancer metastasis.

Surgical neurology international Pub Date : 2024-08-30 eCollection Date: 2024-01-01 DOI:10.25259/SNI_603_2024
Ryo Kanematsu, Junya Hanakita, Toshiyuki Takahashi, Manabu Minami, Koichi Mitsuya
{"title":"Long-term survival following molecular-targeted therapy for intramedullary non-small-cell lung cancer metastasis.","authors":"Ryo Kanematsu, Junya Hanakita, Toshiyuki Takahashi, Manabu Minami, Koichi Mitsuya","doi":"10.25259/SNI_603_2024","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Intramedullary spinal cord metastases (ICSMs) are very rarely curable; these patients typically have very short-term survival rates. Here, a 22-year-old male with non-small-cell lung cancer (NSCLC) later developed ICSM twice; the first C4-C7 tumor responded well to surgery, radiation, and alectinib molecular-targeted therapy. The secondary ICSM C1 lesion seen years later (i.e., likely due to alectinib having been stopped) resolved once alectinib was again administered.</p><p><strong>Case description: </strong>A 22-year-old male with a limited smoking history presented with advanced non-small-cell lung cancer (NSCLC) treated with pulmonary surgery followed by radiotherapy and chemotherapy. Four years later, he developed cervical myelopathy attributed to a C4-C7 stage IV NSCLC ICSM (i.e., notably associated with an anaplastic lymphoma kinase [ALK] rearrangement). After cervical surgery and irradiation (40 Gy/20 fr) of the resection cavity, he was also given alectinib; the patient remained disease-free for the next 7 years, remaining on alectinib. However, 1 year after alectinib was discontinued, he experienced a newly occurrent C1 ICSM lesion; the alectinib was restarted, and his tumor regressed over the next 3 years. At present, 14 years after the original ICSM surgery, the patient remains disease free but continued alectinib (Karnofsky Performance Scale: 90%).</p><p><strong>Conclusion: </strong>Although the prognosis for ICSM is generally poor, molecular-targeted therapies, such as alectinib, as administered in this case, may provide long-term survival for patients with ALK-positive NSCLC tumors.</p>","PeriodicalId":94217,"journal":{"name":"Surgical neurology international","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380904/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical neurology international","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25259/SNI_603_2024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Intramedullary spinal cord metastases (ICSMs) are very rarely curable; these patients typically have very short-term survival rates. Here, a 22-year-old male with non-small-cell lung cancer (NSCLC) later developed ICSM twice; the first C4-C7 tumor responded well to surgery, radiation, and alectinib molecular-targeted therapy. The secondary ICSM C1 lesion seen years later (i.e., likely due to alectinib having been stopped) resolved once alectinib was again administered.

Case description: A 22-year-old male with a limited smoking history presented with advanced non-small-cell lung cancer (NSCLC) treated with pulmonary surgery followed by radiotherapy and chemotherapy. Four years later, he developed cervical myelopathy attributed to a C4-C7 stage IV NSCLC ICSM (i.e., notably associated with an anaplastic lymphoma kinase [ALK] rearrangement). After cervical surgery and irradiation (40 Gy/20 fr) of the resection cavity, he was also given alectinib; the patient remained disease-free for the next 7 years, remaining on alectinib. However, 1 year after alectinib was discontinued, he experienced a newly occurrent C1 ICSM lesion; the alectinib was restarted, and his tumor regressed over the next 3 years. At present, 14 years after the original ICSM surgery, the patient remains disease free but continued alectinib (Karnofsky Performance Scale: 90%).

Conclusion: Although the prognosis for ICSM is generally poor, molecular-targeted therapies, such as alectinib, as administered in this case, may provide long-term survival for patients with ALK-positive NSCLC tumors.

髓内非小细胞肺癌转移分子靶向治疗后的长期生存率。
背景:髓内脊髓转移瘤(ICSM)很少能治愈,这些患者的生存期通常很短。这里有一名患有非小细胞肺癌(NSCLC)的22岁男性患者,后来出现了两次髓内脊髓转移瘤;第一次C4-C7肿瘤对手术、放疗和阿来替尼分子靶向治疗反应良好。数年后出现的第二次ICSM C1病变(可能是由于阿来替尼停药所致)在再次使用阿来替尼后得到缓解:一名 22 岁的男性,吸烟史有限,曾因晚期非小细胞肺癌(NSCLC)接受肺部手术治疗,随后接受放疗和化疗。四年后,他出现了颈椎脊髓病,归因于C4-C7期NSCLC ICSM(即明显伴有无性淋巴瘤激酶[ALK]重排)。在进行了颈椎手术和切除腔照射(40 Gy/20 fr)后,他还接受了阿来替尼治疗;在接下来的 7 年中,患者一直保持无病状态,并继续服用阿来替尼。然而,在停用阿来替尼 1 年后,他又出现了新的 C1 ICSM 病变;阿来替尼被重新启用,在接下来的 3 年中,他的肿瘤有所消退。目前,距离最初的 ICSM 手术已经过去了 14 年,该患者仍未患病,但仍在继续服用阿来替尼(卡诺夫斯基表现评分:90%):结论:尽管ICSM的预后普遍较差,但分子靶向疗法,如本病例中使用的阿来替尼,可为ALK阳性NSCLC肿瘤患者提供长期生存。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信